The HER3 inhibitors Market constitutes an emerging therapeutic frontier within cancer medicine, propelled by revolutionary scientific insights, refined patient selection approaches, and intensified focus on addressing therapeutic resistance pathways. HER3 (ErbB3), formerly regarded as a catalytically inactive component of the ErbB receptor network, has emerged as a critical mediator of adaptive...